Effectiveness of Changing the Class of Molecularly Targeted Agent after Disease Progression during Initial Molecularly Targeted Therapy for Luminal Advanced/Metastatic Breast Cancer-Reference-Cited by-同舟云学术

Effectiveness of Changing the Class of Molecularly Targeted Agent after Disease Progression during Initial Molecularly Targeted Therapy for Luminal Advanced/Metastatic Breast Cancer

Published:2023-04-25 Issue:2 Volume:90 Page:179-185
ISSN:1345-4676
Container-title:Journal of Nippon Medical School
language:en
Short-container-title:J Nippon Med Sch

Author:

Nakano Satoko¹,Mibu Akemi¹,Kato Shunsuke²,Yamaguchi Shigeo³,Suzuki Yuna¹,Tanimura Kaoru⁴,Sano Masataka⁵

Affiliation:

1. Department of Breast Surgery, Kawaguchi Municipal Medical Center

2. Medical Oncology Department, Juntendo University

3. Surgical Department, Keio University School of Medicine

4. Division of Breast and Endocrine Surgery, Department of Surgery, Nihon University School of Medicine

5. Faculty of Commerce, Takushoku University

Publisher

Medical Association of Nippon Medical School

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/jnms/90/2/90_JNMS.2023_90-205/_pdf

Reference29 articles.

1. 1. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375 (20):1925-36. doi: 10.1056/NEJMoa1607303. PubMed PMID: 27959613.

2. 2. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17 (4):425-39. doi: 10.1016/S1470-2045 (15) 00613-0. PubMed PMID: 26947331.

3. 3. Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373 (3):209-19. doi: 10.1056/NEJMoa1505270. PubMed PMID: 26030518.

4. 4. Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379 (20):1926-36. doi: 10.1056/NEJMoa1810527. PubMed PMID: 30345905.

5. 5. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375 (18):1738-48. doi: 10.1056/NEJMoa1609709. PubMed PMID: 27717303.